G3BP1-mediated stress granule assembly via liquid-liquid phase separation

Exploratory Score: 0.900 Price: $0.50 eukaryotic cells Status: proposed

What This Experiment Tests

Exploratory experiment designed to discover new patterns targeting G3BP1 in eukaryotic cells. Primary outcome: demonstration of G3BP1-mediated LLPS in stress granule formation

Description

This study investigated the molecular mechanisms underlying stress granule (SG) assembly, focusing on G3BP1 as a central regulator. The researchers demonstrated that stress granules assemble through liquid-liquid phase separation (LLPS) arising from protein-RNA interactions distributed across a core network. They showed that G3BP1 functions as a molecular switch that triggers RNA-dependent LLPS in response to increased intracellular free RNA concentrations. The study examined how three distinct intrinsically disordered regions (IDRs) in G3BP1 regulate its propensity for LLPS, and how this process is fine-tuned by phosphorylation within the IDRs. Additionally, they investigated how G3BP1-binding factors provide positive or negative cooperativity to strengthen or weaken the core SG network, thereby regulating SG assembly.

TARGET GENE
MODEL SYSTEM
eukaryotic cells
ESTIMATED COST
$0
TIMELINE
0 months
PATHWAY
stress granule assembly pathway
SOURCE
extracted_from_pmid_32302571
PRIMARY OUTCOME
demonstration of G3BP1-mediated LLPS in stress granule formation

Scoring Dimensions

Info Gain 0.00 (25%) Feasibility 0.00 (20%) Hyp Coverage 0.00 (20%) Cost Effect. 0.00 (15%) Novelty 0.00 (10%) Ethical Safety 0.00 (10%) 0.900 composite

📖 Wiki Pages

G3BP1 Protein — Ras-GTPase-Activating Protein-BindproteinRNA Metabolism Dysregulation in 4R-TauopathiesmechanismRNA Therapeutics: Investment Landscape AnalysisinvestmentRNA Metabolism in Alzheimer's DiseasemechanismRNA Metabolism in NeurodegenerationmechanismRNA Binding Fox-3 Homolog (NeuN) (RBFOX3)geneRNA G-quadruplexes in NeurodegenerationmechanismRNA Therapeutics for Neurodegeneration Investment investmentRNA Metabolism Dysfunction in Corticobasal SyndrommechanismRNA Metabolism Dysregulation in Alzheimer's DiseasmechanismG3BP1geneRNA Granule Dysfunction in NeurodegenerationmechanismRNA Binding Fox-1 Homolog 1 (RBFOX1)geneRNA Binding Fox-1 Homolog 2 (RBFOX2)geneRNA Metabolism Dysregulation Pathwaymechanism

Protocol

Constructs: G3BP1 full-length, ΔAcidic (deletion of IDR1, aa 1-139), ΔNTR (deletion of IDR2, aa 1-231), ΔC-term (deletion of IDR3, aa 366-466), and phosphomimetic mutants (S149E, T192E, combined). Express in U2OS cells via lentivirus (GFP-tagged). In vitro LLPS: Purify recombinant G3BP1 variants (His-tagged, Ni-NTA purification). Mix 10 μM G3BP1 with polyU RNA (0-50 ng/μL) in phase separation buffer (25 mM Tris pH 7.5, 150 mM NaCl, 1 mM DTT, 10% PEG-8000). Image droplet formation by DIC and fluorescence microscopy. Quantify: droplet count, size distribution (ImageJ), turbidity (OD600). Cellular SG: Treat U2OS cells with 0.5 mM sodium arsenite (1h) to induce oxidative stress. Fix, immunostain for G3BP1 and TIA1 (SG marker). Count SG per cell (n=100 cells per condition).

...

Expected Outcomes

Quantitative predictions: (1) Full-length G3BP1 forms droplets at >5 μM protein + 10 ng/μL RNA. ΔAcidic and ΔNTR require 2-3x higher concentration (reduced LLPS propensity). ΔC-term completely abolishes LLPS. (2) Phosphomimetic mutants S149E and T192E show 50-70% reduction in droplet formation vs WT. (3) In cells: arsenite induces 15-25 SG per cell (WT G3BP1). ΔAcidic: 8-12 SG, smaller and less persistent. ΔNTR: 5-8 SG, dissolve faster. ΔC-term: <2 SG per cell. (4) USP10 co-expression increases SG size by 40-60%, recovery time by 2-fold. Caprin1 reduces SG count by 30-40%.

...

Success Criteria

Primary: WT G3BP1 forms LLPS droplets in vitro (turbidity >0.3 OD600, p<0.001 vs. no RNA control) and SG in cells (>10 per cell after arsenite, p<0.001 vs. untreated). IDR deletions reduce both by >50% (p<0.01 for each vs. WT). Secondary: (1) Phosphomimetics reduce SG count >40% (p<0.01). (2) USP10 enhances SG persistence (>1.5-fold recovery time, p<0.05). (3) FRAP demonstrates liquid-like properties (mobile fraction >50%, exponential recovery, R²>0.95). (4) Dose-response to RNA shows cooperative binding (Hill coefficient >1.5).

...

Related Hypotheses (6)

Phase-Separated Organelle Targeting0.729
Stress Granule Phase Separation Modulators0.720
RNA Granule Nucleation Site Modulation0.662
Liquid-Liquid Phase Separation Modifier Therapy0.551
Ubiquitin-Mediated Liquid-to-Solid Transition Prevention0.730

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.